Clinical trials: Non-segmental Vitiligo
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Non-Segmental Vitiligo
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.
- Trial name
- NCT07667569
- Testing
- ACT-777991
- Volunteers
- 30 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Non-segmental Vitiligo
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
- Trial name
- NCT07172347
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Non-Segmental Vitiligo (NSV)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04052425
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Vitiligo
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period.
- Trial name
- NCT07181187
- Testing
- MH004 Ointment, Vehicle Ointment
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Trial name
- Tranquillo (NCT05583526)
- Testing
- Ritlecitinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 607 people
- Sponsor
- Pfizer
Vitiligo
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
- Trial name
- NCT07682506
- Testing
- MH004 1.0% Ointment
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Vitiligo
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
- Trial name
- NCT04811131
- Testing
- ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment
- Where
- 5 sites in United States
- Volunteers
- 114 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Non-segmental Vitiligo
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it.
- Trial name
- NCT06113328
- Testing
- MK-6194
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Segmental Vitiligo
Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China
The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China This study is a cross-sectional…
- Trial name
- NCT07058051
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- AbbVie
Vitiligo
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- Viti-Up (NCT06118411)
- Testing
- Upadacitinib, NB-UVB (narrow-band ultraviolet B) Phototherapy
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 614 people
- Sponsor
- AbbVie
Vitiligo
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
- Trial name
- NCT06905873
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Forte Biosciences, Inc.
Active Non-segmental Vitiligo
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks.
- Trial name
- NCT03715829
- Testing
- PF-06651600, PF06700841, narrow-band UVB phototherapy
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 366 people
- Sponsor
- Pfizer
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Non-segmental Vitiligo
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
- Trial name
- NCT04487860
- Testing
- AS012
- Where
- 31 sites in United States, India
- Volunteers
- 327 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Non-segmental Vitiligo
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
- Trial name
- NCT07251595
- Testing
- SHR0302 Tablets, SHR0302 Base Gel
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo, Non-Segmental Vitiligo (NSV)
Study of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
- Trial name
- D2570-206 (NCT07625891)
- Testing
- D-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3
- Where
- China
- Volunteers
- 160 people
- Sponsor
- InventisBio Co., Ltd